ClinicalTrials.gg
CompletedNCT00708435Updated Feb 3, 2014Results posted

Efficacy and Safety Study of BERIPLEX® P/N (Kcentra) Compared With Plasma in Patients With Acute Major Bleeding Caused by Anticoagulant Therapy

A Phase 3 interventional study of Beriplex® P/N (Kcentra) and Fresh frozen plasma in Blood Coagulation Disorders and Acute Major Bleeding, sponsored by CSL Behring. Completed at 69 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-02-03.

Sponsored by CSL Behring (part of CSL Limited) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
216
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 55 studies in Blood Coagulation Disorders with a site in United States — 6 open to participants now, 6 under way, 2 of them phase 3. Blood Coagulation Disorders · United States.

Enrollment
2nd of 38
216 · median 33
Started
2008
the only one that year
Phase 3
13 of 55
2 open now
Registered
15th of 55
by date
Lead sponsor
2 of 55
CSL Behring

Among the 55 studies in Blood Coagulation Disorders with a site in United States, this one is the 2nd largest by enrollment of the 38 interventional ones that give a count, is the only one that started in 2008, is one of 13 in phase 3, and was the 15th registered.

Blood Coagulation Disorders

148 studies on the registry are indexed under Blood Coagulation Disorders; 16 are open to participants now.

Browse Blood Coagulation Disorders studies →

Open to participants now

6 of the 55 studies in Blood Coagulation Disorders with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 13 Blood Coagulation Disorders studies recruiting now, 8 (62%) set no upper age limit and 4 (31%) stop at 75 or younger; 6 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Blood Coagulation Disorders with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate efficacy, safety and tolerance of BERIPLEX® P/N (Kcentra) compared with plasma in regard to rapid reversal of coagulopathy induced by coumarin derivatives in subjects who require immediate correction of INR (International Normalized Ratio)and to stop an acute major bleeding.

03

Conditions studied

  • Blood Coagulation Disorders
  • Acute Major Bleeding

Keywords

  • Anticoagulant reversal
  • Prothrombin
  • Complex
  • Concentrate
  • Coagulopathy
  • induced by
  • coumarin
  • derivatives
  • Kcentra
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects ≥ 18 years
  • Subjects who have received oral vitamin K-antagonist therapy
  • Subjects who have acute major bleeding, defined as one of the following: life-threatening or potentially life-threatening, acute bleeding associated with a fall in (Hb) level ≥ 2g/dL, bleeding requiring blood product transfusion
  • ≥ 2 within 3 hours before start of study treatment
  • has been obtained

Exclusion criteria

Exclusion Criteria:

  • Expected survival of less than 3 days, or expected surgery in less than 1 day
  • Acute trauma for which reversal of vitamin K antagonists alone would not be expected to control the acute bleeding event
  • Use of unfractionated or low molecular weight heparin use from 24 hours prior to enrollment or expected need within 24 hours after start of infusion
  • For patients with ICH: Glasgow coma score (GCS) \< 7; intracerebral hematoma volume > 30cc as assessed by ABC/21; for subdural hematomas: maximum thickness ≥ 10 mm, midline shift ≥ 5 mm; for subarachnoid hemorrhage: any evidence of hydrocephalus; infratentorial ICH location; epidural hematomas; intraventricular extension of hemorrhage; modified Rankin score (mRS) of >3 prior to ICH
  • History of thrombotic event, myocardial infarction, disseminated intravascular coagulation, cerebral vascular accident, , unstable angina pectoris, or severe peripheral vascular disease within 3 months of enrollment
  • Known history of antiphospholipid antibody syndrome or lupus anticoagulant antibodies
  • Suspected or confirmed sepsis at time of enrollment
  • Administration of whole blood, plasma, plasma fractions or within 2 weeks prior to inclusion into the study
  • Large blood vessel rupture (e.g. in advanced cancer patient)
  • Pre-existing progressive fatal disease with a of less than 2 months
  • Known inhibitors to coagulation factors II, VII, IX, or X; or hereditary protein C or protein S deficiency; or heparin-induced, type II thrombocytopenia
  • Treatment with any other medicinal product within 30 days prior to inclusion into the study
  • Presence or history of to components of the study medication
  • Pregnant or breast-feeding women
  • Prior inclusion in this study or any other CSL Behring-sponsored Beriplex study
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
216 participants (actual)

Study arms

  • Experimental
    Beriplex® P/N

    Biological: Beriplex® P/N (Kcentra)

  • Active comparator
    Fresh frozen plasma

    Biological: Fresh frozen plasma

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Hemostatic Efficacy of Stopping an Ongoing Major Bleed

    Hemostatic efficacy was determined by a blinded independent board as excellent, good, or poor/none, based on prespecified definitions. Assessments of visible or non-visible musculoskeletal bleeding were made at 1 and 4 hours after the end of infusion. Hemostatic efficacy was the binary endpoint of effective or non-effective hemostasis, where 'effective' was a hemostatic efficacy rating of "excellent" or "good," and 'non-effective' was a hemostatic efficacy rating of "poor/none".

    Time frame: At 1 and 4 hours after the end of infusion

  2. Percentage of Participants Who Had a Rapid Decrease of the International Normalized Ratio (INR)

    A rapid decrease of the international normalized ratio (INR) was defined as an INR ≤ 1.3 at 30 minutes after the end of the infusion. The INR is a standard way to describe the time it takes for blood to clot; an INR range of 0.8 to 1.2 is considered normal for a healthy person who is not using oral anticoagulant therapy.

    Time frame: 30 minutes after end of infusion

Secondary outcomes

  1. Percentage of Participants Who Had Hemostatic Efficacy for Visible or Non-visible Musculoskeletal Bleeding

    Hemostatic efficacy was determined by a blinded independent board as excellent, good, or poor/none, based on prespecified definitions. Assessments of visible or non-visible musculoskeletal bleeding were made at 3 and 6 hours after the start of infusion. Hemostatic efficacy was the binary endpoint of effective or non-effective hemostasis, where 'effective' was a hemostatic efficacy rating of "excellent" or "good," and 'non-effective' was a hemostatic efficacy rating of "poor/none".

    Time frame: At 3 and 6 hours after the start of infusion

  2. Incremental in Vivo Recovery (IVR) (Response) of Factors II, VII, IX, and X, Protein C, and Protein S for Beriplex

    The incremental IVR \[(IU/dL)/(IU/kg)\] was calculated as follows: (IU/dL activity rise in plasma)/(IU/kg body weight infused) = \[maximum increase in component plasma level within 3 hours compared to pre-infusion (IU/dL)\]/{\[exact dose of component in drug administered (IU)\]/\[body weight (kg)\]}.

    Time frame: Before infusion and up to 3 h after the start of infusion

  3. Plasma Levels of Factors II, VII, IX, and X, Protein C, and Protein S

    Plasma levels are presented as the percentage of normal at pre-infusion and 30 min and 24 h after the start of infusion. The plasma level assay results are reported as a potency relative to a standard, where 100% is considered to be normal.

    Time frame: From preinfusion until 24 h after the start of infusion

  4. Percentage of Participants With INR Correction at Various Times After the Start of Infusion

    The time taken from the start of infusion to INR correction (defined as an INR ≤ 1.3) was recorded. The percentage of participants with INR correction was calculated at 0.5, 1, 3, 6, 12, and 24 h after the start of infusion.

    Time frame: From the start of infusion until INR correction; calculated at 0.5, 1, 3, 6, 12, and 24 h after the start of infusion.

  5. Percentage of Participants With INR Correction at Various Times After Randomization

    The time taken from randomization to INR correction (defined as an INR ≤ 1.3) was recorded. The percentage of participants with INR correction was calculated at 2.5, 3, 5, 8, 14, and 26 h after randomization.

    Time frame: From randomization until INR correction; calculated at 2.5, 3, 5, 8, 14, and 26 h after randomization.

  6. Transfusion of Red Blood Cells

    Red blood cells were packed red blood cells (PRBCs).

    Time frame: From the start of infusion until 24 h after the start of infusion

  7. Use of Other Blood Products and Hemostatic Agents

    Other blood products and hemostatic agents containing coagulation factors (such as whole blood, plasma, albumin, platelets) not including PRBCs.

    Time frame: From the start of infusion until 24 h after the start of infusion

  8. 45-Day All-cause Mortality

    Time frame: Until Day 45

  9. Overall Treatment-emergent Adverse Events (TEAEs)

    Number of participants with TEAEs. Treatment-related AEs were defined as events whose relationship to study treatment was definitely related, probably related, or possibly related in the opinion of the investigator. AEs with missing relationship were considered related to treatment. Serious TEAEs were treatment-emergent SAEs. Deaths reported up to and including Day 45; one additional Beriplex death occurred after Day 45.

    Time frame: From the start of infusion up to the allowed time window of the Day 10 visit for non-serious AEs and from the start of infusion up to the allowed time window of the Day 45 visit for SAEs.

07

Results

Posted Aug 13, 2013

Participant flow

Participant flow — Overall Study
MilestoneBeriplex® P/NFresh Frozen Plasma
Started107109
Completed8292
Not completed2517
Withdrew: Death / serious adverse event105
Withdrew: Lost to follow-up94
Withdrew: Withdrawal by subject37
Withdrew: Adverse event10
Withdrew: Protocol violation01
Withdrew: Intervention by primary care physician10
Withdrew: Refused hospitalization10

Outcome measures

PrimaryPercentage of Participants Achieving Hemostatic Efficacy of Stopping an Ongoing Major Bleed

Hemostatic efficacy was determined by a blinded independent board as excellent, good, or poor/none, based on prespecified definitions. Assessments of visible or non-visible musculoskeletal bleeding were made at 1 and 4 hours after the end of infusion. Hemostatic efficacy was the binary endpoint of effective or non-effective hemostasis, where 'effective' was a hemostatic efficacy rating of "excellent" or "good," and 'non-effective' was a hemostatic efficacy rating of "poor/none".

Time frame:
At 1 and 4 hours after the end of infusion
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Hemostatic Efficacy of Stopping an Ongoing Major Bleed
percentage of participantsBeriplex® P/NFresh Frozen Plasma
Percentage of Participants Achieving Hemostatic Efficacy of Stopping an Ongoing Major Bleed72.4 (63.6 to 81.3)65.4 (56.2 to 74.5)
Statistical analysis
  • Beriplex® P/N vs Fresh Frozen Plasma · 95% confidence interval · Difference in effective hemostasis (%): 7.1 · 95% CI -5.8 to 19.9Both primary endpoints had to be non-inferior for Beriplex to be non-inferior. There is no P-value as non-inferiority was assessed via the 95% CI calculation for the difference (Beriplex minus plasma) in the % of subjects with effective hemostasis.
PrimaryPercentage of Participants Who Had a Rapid Decrease of the International Normalized Ratio (INR)

A rapid decrease of the international normalized ratio (INR) was defined as an INR ≤ 1.3 at 30 minutes after the end of the infusion. The INR is a standard way to describe the time it takes for blood to clot; an INR range of 0.8 to 1.2 is considered normal for a healthy person who is not using oral anticoagulant therapy.

Time frame:
30 minutes after end of infusion
Reported as:
Number · percentage of participants
Percentage of Participants Who Had a Rapid Decrease of the International Normalized Ratio (INR)
percentage of participantsBeriplex® P/NFresh Frozen Plasma
Percentage of Participants Who Had a Rapid Decrease of the International Normalized Ratio (INR)62.2 (52.6 to 71.8)9.6 (3.9 to 15.3)
Statistical analysis
  • Beriplex® P/N vs Fresh Frozen Plasma · 95% confidence interval · Difference in the decrease of inr (%): 52.6 · 95% CI 39.4 to 65.9Both primary endpoints had to be non-inferior for Beriplex to be non-inferior. There is no P-value as non-inferiority was assessed via the 95% CI for the difference (Beriplex minus plasma) in the % of subjects with a rapid decrease of the INR.
SecondaryPercentage of Participants Who Had Hemostatic Efficacy for Visible or Non-visible Musculoskeletal Bleeding

Hemostatic efficacy was determined by a blinded independent board as excellent, good, or poor/none, based on prespecified definitions. Assessments of visible or non-visible musculoskeletal bleeding were made at 3 and 6 hours after the start of infusion. Hemostatic efficacy was the binary endpoint of effective or non-effective hemostasis, where 'effective' was a hemostatic efficacy rating of "excellent" or "good," and 'non-effective' was a hemostatic efficacy rating of "poor/none".

Time frame:
At 3 and 6 hours after the start of infusion
Reported as:
Number · percentage of participants
Percentage of Participants Who Had Hemostatic Efficacy for Visible or Non-visible Musculoskeletal Bleeding
percentage of participantsBeriplex® P/NFresh Frozen Plasma
Percentage of Participants Who Had Hemostatic Efficacy for Visible or Non-visible Musculoskeletal Bleeding73.5 (64.7 to 82.2)67.3 (58.3 to 76.3)
SecondaryIncremental in Vivo Recovery (IVR) (Response) of Factors II, VII, IX, and X, Protein C, and Protein S for Beriplex

The incremental IVR \[(IU/dL)/(IU/kg)\] was calculated as follows: (IU/dL activity rise in plasma)/(IU/kg body weight infused) = \[maximum increase in component plasma level within 3 hours compared to pre-infusion (IU/dL)\]/{\[exact dose of component in drug administered (IU)\]/\[body weight (kg)\]}.

Time frame:
Before infusion and up to 3 h after the start of infusion
Reported as:
Mean · (IU/dL)/(IU/kg body weight)
Incremental in Vivo Recovery (IVR) (Response) of Factors II, VII, IX, and X, Protein C, and Protein S for Beriplex
(IU/dL)/(IU/kg body weight)Beriplex® P/N
Factor II2.00 ± 0.879
Factor VII2.15 ± 2.958
Factor IX1.29 ± 0.711
Factor X1.96 ± 0.871
Protein C2.04 ± 0.958
Protein S2.17 ± 1.661
SecondaryPlasma Levels of Factors II, VII, IX, and X, Protein C, and Protein S

Plasma levels are presented as the percentage of normal at pre-infusion and 30 min and 24 h after the start of infusion. The plasma level assay results are reported as a potency relative to a standard, where 100% is considered to be normal.

Time frame:
From preinfusion until 24 h after the start of infusion
Reported as:
Mean · percentage of normal
Plasma Levels of Factors II, VII, IX, and X, Protein C, and Protein S
percentage of normalBeriplex® P/NFresh Frozen Plasma
Factor II, pre-infusion (n = 98; 103)20.1 ± 14.5622.3 ± 22.39
Factor II, 0.5 h after infusion start (n = 88; 90)87.5 ± 44.4831.9 ± 22.55
Factor II, 24 h after infusion start (n = 92; 99)77.1 ± 22.0658.1 ± 19.55
Factor VII, pre-infusion (n = 98; 103)25.9 ± 35.0123.5 ± 23.45
Factor VII, 0.5h after infusion start (n = 88; 90)60.5 ± 45.2334.6 ± 26.18
Factor VII, 24 h after infusion start (n = 92; 99)114.8 ± 165.28101.3 ± 79.01
Factor IX, pre-infusion (n = 98; 103)36.1 ± 22.5639.0 ± 27.56
Factor IX, 0.5 h after infusion start (n = 88; 90)76.8 ± 35.4747.7 ± 26.78
Factor IX, 24 h after infusion start (n = 92; 99)88.5 ± 35.6593.0 ± 29.95
Factor X, pre-infusion (n = 98; 102)13.0 ± 11.2514.7 ± 18.83
Factor X, 0.5 h after infusion start (n = 88; 90)99.8 ± 56.0723.9 ± 20.40
Factor X, 24 h after infusion start (n = 92; 99)83.7 ± 27.0558.2 ± 21.78
Protein C, pre-infusion (n = 98; 103)39.3 ± 17.1541.1 ± 18.84
Protein C, 0.5 h after infusion start (n = 88; 90)110.3 ± 47.3750.9 ± 24.78
Protein C, 24h after infusion start (n = 92; 98)90.3 ± 27.1982.8 ± 24.34
Protein S, pre-infusion (n = 97; 102)27.8 ± 11.3429.6 ± 12.97
Protein S, 0.5 h after infusion start (n = 88; 89)59.4 ± 28.5638.6 ± 20.45
Protein S, 24 h after infusion start (n = 91; 97)47.8 ± 16.5445.4 ± 16.00
SecondaryPercentage of Participants With INR Correction at Various Times After the Start of Infusion

The time taken from the start of infusion to INR correction (defined as an INR ≤ 1.3) was recorded. The percentage of participants with INR correction was calculated at 0.5, 1, 3, 6, 12, and 24 h after the start of infusion.

Time frame:
From the start of infusion until INR correction; calculated at 0.5, 1, 3, 6, 12, and 24 h after the start of infusion.
Reported as:
Number · percentage of participants
Percentage of Participants With INR Correction at Various Times After the Start of Infusion
percentage of participantsBeriplex® P/NFresh Frozen Plasma
0.5 h40
1 h690
3 h719
6 h7816
12 h8036
24 h8858
SecondaryPercentage of Participants With INR Correction at Various Times After Randomization

The time taken from randomization to INR correction (defined as an INR ≤ 1.3) was recorded. The percentage of participants with INR correction was calculated at 2.5, 3, 5, 8, 14, and 26 h after randomization.

Time frame:
From randomization until INR correction; calculated at 2.5, 3, 5, 8, 14, and 26 h after randomization.
Reported as:
Number · percentage of participants
Percentage of Participants With INR Correction at Various Times After Randomization
percentage of participantsBeriplex® P/NFresh Frozen Plasma
2.5 h592
3 h672
5 h7610
8 h7922
14 h8438
26 h9070
SecondaryTransfusion of Red Blood Cells

Red blood cells were packed red blood cells (PRBCs).

Time frame:
From the start of infusion until 24 h after the start of infusion
Reported as:
Mean · Units of PRBCs
Transfusion of Red Blood Cells
Units of PRBCsBeriplex® P/NFresh Frozen Plasma
Transfusion of Red Blood Cells1.4 ± 1.771.2 ± 1.57
SecondaryUse of Other Blood Products and Hemostatic Agents

Other blood products and hemostatic agents containing coagulation factors (such as whole blood, plasma, albumin, platelets) not including PRBCs.

Time frame:
From the start of infusion until 24 h after the start of infusion
Reported as:
Mean · Units of blood products
Use of Other Blood Products and Hemostatic Agents
Units of blood productsBeriplex® P/NFresh Frozen Plasma
Use of Other Blood Products and Hemostatic Agents0.3 ± 1.360.3 ± 0.87
Secondary45-Day All-cause Mortality
Time frame:
Until Day 45
Reported as:
Number · participants
45-Day All-cause Mortality
participantsBeriplex® P/NFresh Frozen Plasma
45-Day All-cause Mortality95
SecondaryOverall Treatment-emergent Adverse Events (TEAEs)

Number of participants with TEAEs. Treatment-related AEs were defined as events whose relationship to study treatment was definitely related, probably related, or possibly related in the opinion of the investigator. AEs with missing relationship were considered related to treatment. Serious TEAEs were treatment-emergent SAEs. Deaths reported up to and including Day 45; one additional Beriplex death occurred after Day 45.

Time frame:
From the start of infusion up to the allowed time window of the Day 10 visit for non-serious AEs and from the start of infusion up to the allowed time window of the Day 45 visit for SAEs.
Reported as:
Number · participants
Overall Treatment-emergent Adverse Events (TEAEs)
participantsBeriplex® P/NFresh Frozen Plasma
Any TEAE6671
At least possibly treatment-related TEAE1023
Serious TEAE3226
Death105

Adverse events

Collected over From the start of infusion up to the allowed time window of the Day 45 visit for SAEs, and from the start of infusion up to the allowed time window of the Day 10 visit for non-serious AEs.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Beriplex® P/N—32/103 (31.1%)46/103 (44.7%)
Fresh Frozen Plasma—26/109 (23.9%)40/109 (36.7%)
Most frequent serious events
Showing 10 of 54
Most frequent serious events
EventBeriplex® P/NFresh Frozen Plasma
Cardiac failure congestiveCardiac disorders1/1034/109
Ischaemic strokeNervous system disorders3/1030/109
Atrial flutterCardiac disorders2/1030/109
Haemorrhage intracranialNervous system disorders2/1030/109
PneumoniaInfections and infestations2/1031/109
Respiratory failureRespiratory, thoracic and mediastinal disorders2/1031/109
Myocardial ischaemiaCardiac disorders0/1032/109
EncephalopathyNervous system disorders0/1032/109
Subarachnoid haemorrhageNervous system disorders0/1032/109
AnaemiaBlood and lymphatic system disorders0/1032/109
Most frequent other events
Showing 10 of 31
Most frequent other events
EventBeriplex® P/NFresh Frozen Plasma
HeadacheNervous system disorders10/1034/109
ConstipationGastrointestinal disorders5/1038/109
Oedema peripheralGeneral disorders6/1037/109
InsomniaPsychiatric disorders6/1033/109
HypokalaemiaMetabolism and nutrition disorders2/1036/109
HypotensionVascular disorders5/1033/109
PyrexiaGeneral disorders4/1034/109
DizzinessNervous system disorders4/1030/109
Pleural effusionRespiratory, thoracic and mediastinal disorders4/1030/109
TachycardiaCardiac disorders4/1031/109

Baseline characteristics

The Intention-to-treat population comprised all subjects who were (1) eligible for the study and had (2) signed informed consent and were randomized to 1 of the 2 treatment groups regardless of whether the subjects received study product. In the ITT population, subjects were analyzed "as randomized".

Age, Customized
Age, Customized(Participants)Beriplex® P/NFresh Frozen PlasmaTotal
< 65 years363268
≥ 65 to < 75 years282957
≥ 75 years434891
Sex: Female, Male
Sex: Female, Male(Participants)Beriplex® P/NFresh Frozen PlasmaTotal
Female5255107
Male5554109
08

Study locations

69 sites
  • Study Site
    Birmingham, Alabama 35248-3280, United States
  • Study Site
    Los Angeles, California 90033, United States
  • Study Site
    San Franciso, California 94115, United States
  • Study Site
    Newark, Delaware 19718, United States
  • Study Site
    Orlando, Florida 32806, United States
  • Study Site
    Tampa, Florida 33606, United States
  • Study Site
    Chicago, Illinois 60612, United States
  • Study Site
    Oak Park, Illinois 60302, United States
  • Study Site
    Hazard, Kentucky 41701, United States
  • Study Site
    Baltimore, Maryland 21201, United States
  • Study Site
    Baltimore, Maryland 21205, United States
  • Study Site
    Boston, Massachusetts 02114, United States
  • Study Site
    Worchester, Massachusetts 01655, United States
  • Study Site
    Ann Arbor, Michigan 48106, United States
  • Study Site
    Royal Oak, Michigan 48073, United States
  • Study Site
    Duluth, Minnesota 55805, United States
  • Study Site
    Minneapolis, Minnesota 55114, United States
  • Study Site
    Jackson, Mississippi 39216, United States
  • Study Site
    St. Louis, Missouri 63110, United States
  • Study Site
    Albuquerque, New Mexico 87131, United States
  • Study Site
    Albany, New York 12208, United States
  • Study Site
    Johnson City, New York 13790, United States
  • Study Site
    New York, New York 10003, United States
  • Study Site
    New York, New York 10029, United States
  • Study Site
    New York, New York 10032, United States
  • Study Site
    Rochester, New York 14642, United States
  • Study Site
    Staten Island, New York 10305, United States
  • Study Site
    Durham, North Carolina 27710, United States
  • Study Site
    Allentown, Pennsylvania 18103, United States
  • Study Site
    Hershey, Pennsylvania 17033, United States
  • Study Site
    Philadelphia, Pennsylvania 19107, United States
  • Study Site
    Philadelphia, Pennsylvania 19140, United States
  • Study Site
    West Reading, Pennsylvania 19611, United States
  • Study Site
    Austin, Texas 78701, United States
  • Study Site
    El Paso, Texas 79905, United States
  • Study Site 2
    Houston, Texas 77030, United States
  • Study Site
    Houston, Texas 77030, United States
  • Study Site
    Temple, Texas 76508, United States
  • Study Site
    Salt Lake City, Utah 84132, United States
  • Study Site
    Charlottesville, Virginia 22908, United States
  • Study Site
    Richmond, Virginia 23298, United States
  • Study Site 1
    Minsk, Belarus
  • Study Site 2
    Minsk, Belarus
  • Study Site
    Pleven, Bulgaria
  • Study Site
    Plovdiv, Bulgaria
  • Study Site
    Rousse, Bulgaria
  • Study Site 1
    Sofia, Bulgaria
  • Study Site 2
    Sofia, Bulgaria
  • Study Site 3
    Sofia, Bulgaria
  • Study Site 4
    Sofia, Bulgaria
  • Study Site
    Brasov, Romania
  • Study Site 1
    Bucharest, Romania
  • Study Site 2
    Bucharest, Romania
  • Study Site 3
    Bucharest, Romania
  • Study Site
    Cluj-Napoca, Romania
  • Study Site
    Timisoara, Romania
  • Study Site
    Arkhangelsk, Russian Federation
  • Study Site 1
    Barnaul, Russian Federation
  • Study Site 2
    Barnaul, Russian Federation
  • Study Site
    Kazan, Russian Federation
  • Study Site
    Kemerovo, 650002, Russian Federation
  • Study Site 1
    Moscow, Russian Federation
  • Study Site 2
    Moscow, Russian Federation
  • Study Site 1
    Nizhny Novgorod, Russian Federation
  • Study Site 2
    Nizhny Novgorod, Russian Federation
  • Study Site 1
    St. Petersburg, Russian Federation
  • Study Site 2
    St. Petersburg, Russian Federation
  • Study Site
    Kharkov, Ukraine
  • Study Site
    Vinnytsa, Ukraine
09

References and documents

Publications

  • Sarode R, Milling TJ Jr, Refaai MA, Mangione A, Schneider A, Durn BL, Goldstein JN. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013 Sep 10;128(11):1234-43. doi: 10.1161/CIRCULATIONAHA.113.002283. Epub 2013 Aug 9. PubMed 23935011 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2008, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2013, 2 years 9 months after primary completion. A results delay was requested in Jul 2011.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2008
First posted
Jul 2, 2008
Start
Jun 2008
Primary completionActual
Nov 2010
CompletionActual
Nov 2010
Results delay requested
Jul 12, 2011
Results first posted
Aug 13, 2013
Last update
Feb 3, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00708435
Lead sponsor
CSL Behring
Responsible party
Sponsor
First posted
Jul 2, 2008
Start date
Jun 2008
Primary completion
Nov 2010
Completion
Nov 2010
Results posted
Aug 13, 2013
Last update
Feb 3, 2014

Study contacts

Program Director, Clinical R&D
study director · CSL Behring
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Prothrombin complex concentrate · Four-factor Prothrombin Complex Concentrate

Start the discussion